NPI: 1336112598 · NORTHPORT, AL 35476 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 02/08/2006
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 02/08/2006 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 18,063 | $253K |
| 2019 | 14,562 | $170K |
| 2020 | 12,551 | $228K |
| 2021 | 8,830 | $183K |
| 2022 | 6,447 | $136K |
| 2023 | 2,674 | $85K |
| 2024 | 1,562 | $43K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 20,174 | 1,443 | $738K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 21,542 | 1,000 | $326K |
| J1756 | Injection, iron sucrose, 1 mg | 4,960 | 1,024 | $19K |
| J1270 | Injection, doxercalciferol, 1 mcg | 11,975 | 878 | $4K |
| 83970 | 480 | 355 | $4K | |
| 82108 | 290 | 233 | $2K | |
| A4657 | Syringe, with or without needle, each | 1,009 | 795 | $2K |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 47 | 24 | $1K |
| 83550 | 378 | 283 | $800.36 | |
| 82728 | 361 | 265 | $717.44 | |
| 85045 | 735 | 607 | $601.80 | |
| 83540 | 378 | 283 | $525.64 | |
| 85041 | 796 | 638 | $455.39 | |
| 85048 | 793 | 637 | $423.75 | |
| 87340 | 15 | 14 | $76.10 | |
| 86706 | 15 | 14 | $72.75 | |
| 90674 | 13 | 12 | $24.05 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 23 | 12 | $0.00 |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 705 | 429 | $0.00 |